April 24, 2024

Tumor Cell Therapies from Space Biology

Exploring the Network of Cellular Interactions of NK Cells in the Tumor Microenvironment

Kalamazoo, MI

BioGravity LLC will be joining “Exploring the Network of Cellular Interactions of NK Cells in the Tumor Microenvironment”

In this webinar, Dr. Lowdell will discuss the latest data from INmune Bio, Inc and the discovery of a new mechanism of action of its NK-priming immunotherapy, “INKmune”.

INKmune™ is a clinical stage proprietary tumor cell line which is administered intravenously and primes NK cells to kill otherwise resistant tumors. INKmune™-primed NK cells have been shown to kill a wide variety of solid and hematological cancer cells in preclinical studies.

Use of the latest state-of-the-art cell-cell analysis technology that measures cell avidity has demonstrated that INKmune™ increases NK cell killing of tumor cells by strengthening the binding of the NK to the tumor cell. Our preclinical studies show that the robust immune synapse created by INKmune™ priming is greater than that induced by conventional cytokine activation (IL-2 or IL-15) and allows more rapid NK-mediated killing which was confirmed by videomicrography. These INKmune™-primed NK cells are not only more efficient killers of tumor cells but are able to overcome inhibition by regulatory cells and hypoxia in the tumor microenvironment.

It has become evident that beyond conventional assays, which includes cytokine secretion and in vitro cell killing, cellular avidity, i.e.overall effector cell-tumor cell binding strenght, provides key information that can predict in vivo efficacy. LUMICKS’ z-Movi® Cell Avidity Analyzer is a one-in-a-kind instrument that allows the measurements of hundreds of effector-tumor cell pairs for their interaction strength. As part of this webinar, z-Movi’s potential for cell immunotherapy development will be explained and the workflow introduced.

BioGravity LLC and Microgravitational-Induced Cell Signaling
Dr. James Secrest of BioGravity LLC will be reviewing new immunotherapies against cancer using NK cells with an eye toward clinical biotech discovery induced by mechanical unloading. Though a proprietary end-to-end verification path at the WMU Medical Innovation Center, BioGravity’s www.MichiganSpaceStation.com is leading #biotech and #bipharma advances in bispecific antibodies, CAR-T cells, TCR T cells, allogeneic T cells, or other similar strategies of cell interaction and cytokine

Top Therapeutic Companies are using Out-of-This-World Solutions to Cell Signals Using Gravitional Unloading on NK Cells